Board of Directors

  • Andrew J M Richards, Ph.D., CBE (Chairman)

    Andrew Richards is an established biotechnology entrepreneur and investor with extensive experience from the UK biotechnology sector in research, drug development, commercial deals and scale-up of companies. He is the Chairman of Congenica Ltd, Abcodia Ltd, Ieso Digital Health Ltd and Closed Loop Medicine Ltd as well as being a director of Owlstone Medical Ltd, Cancer Research Technology Ltd (the commercial board of Cancer Research UK) and The Scale-Up Institute.

    He is a council member of the UK Medical Research Council.

    Andrew is a Cambridge graduate with a Ph.D. in enzyme chemistry and was a founder of Chiroscience in 1992 and an Executive Director through to the Celltech deal in 1999. Andrew has a track record as a founder, active investor in and director of more than 25 innovative healthcare and life-science companies, including Vectura plc and Arakis Ltd. He has experience as a board director for several public companies, including Chiroscience plc, Vectura plc, IXICO plc and Silence Therapeutics plc.

  • Sarah Howell, Ph.D., Chief Executive Officer

    Sarah Howell was appointed Chief Executive Officer of Arecor in 2015, having joined in 2011 as Chief Operating Officer and Executive Director. During her time at Arecor she has led the transformation of the business into a successful clinical stage biotechnology company. Sarah has a background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas.

    She has served in a number of senior roles in the pharmaceutical industry, including Vice President CMC & Technical Development at BTG Plc., and Director of Outsourced Manufacturing at UCB-Celltech.

    Sarah holds a BSc in Chemistry from the University of Birmingham and a Ph.D. in Physical Organic Chemistry from the University of St Andrews.

  • Susan Lowther, Chief Financial Officer and Company Secretary

    Susan Lowther was appointed Chief Financial Officer and Company Secretary at Arecor in 2019. She brings significant financial leadership experience across a broad range of public and private life science companies. Susan joined Arecor from IXICO plc, an imaging contract research organisation where she defined the financing strategy and raised growth capital taking the company on a path to profitability.

    Previously, she was Chief Financial Officer at Novacyt S.A. where she oversaw the acquisition of Lab21 Limited, CFO at BioWisdom Limited, who were acquired by Instem Plc, and Finance Director of RiboTargets Limited, from start-up until its acquisition by Vernalis plc.

    Susan’s life-sciences career started at Celltech Group plc and included Head of Finance at Lonza Biologics (previously Celltech Biologics). As part of the leadership team, she was responsible for finance, HR, IT and facilities functions in the US and UK.

    Susan has been a member of executive boards since 1997 and a Fellow of the Chartered Institute of Management Accountants since 2003.

  • Sam Fazeli, Ph.D., Non-Executive Director

    Sam Fazeli has served as a member of the Arecor Board of Directors since September 2017 and brings over twenty-two years of experience of conducting equity research as a pharmaceutical analyst, working at firms including Nomura International and HSBC. Currently, he is Director of EMEA Research and Senior Pharmaceutical Analyst at Bloomberg Intelligence in London, where he specialises in global pharmaceuticals.

    Prior to joining Bloomberg in 2010, Sam worked at Piper Jaffray, Ltd. as a pharmaceutical analyst and head of European research. Before transitioning to investment banking, he was a research scientist for seven years. Sam has been ranked a top analyst by both the UK and Pan-European Extel surveys.

    He holds a degree from Cardiff University, and a Ph.D. in pharmacology from the University of London.

  • Jeremy Morgan, Non-Executive Director

    Jeremy completed a Senior Executive Programme in General Management from London Business School and holds a BSc (Hons) in Applied Biology from Coventry University.

    Jeremy Morgan is an experienced Pharmaceutical General Manager, having been responsible for product development and market access, as well as commercial strategy development and product launches at a national, regional and global level.

    Jeremy was Vice President of Diabetes, International, for Eli Lilly & Company from 2014-2017, leading and developing individuals and teams across Europe, Japan, Canada and Australia and working across functions, geographies and products. From 2018-2019 Jeremy served as Chief Operating Officer at market access and reimbursement specialists PHMR Limited, where he was also Non-Executive Chairman from 2019-2020. He is currently Senior Vice President, Commercial, for Kyowa Kirin International plc.

  • Alan E Smith, Ph.D., FRS, CBE, Non-Executive Director

    Alan Smith is the former Senior Vice President and the Chief Scientific Officer of Genzyme Corporation, Cambridge MA, where he had overall responsibility for the company’s science. Prior to its acquisition by Genzyme in 1989, Alan was the Vice President and Scientific Director of Integrated Genetics, a start-up biotechnology company. From 1980-84 he was head of the biochemistry division at the National Institute of Medical Research, Mill Hill, London. Presently, Alan sits on the Scientific Advisory Boards of Pharnext, a genomics company in Paris, France and he is on the Board of Directors of Candel Therapeutics (formerly Advantagene), an immune-oncology company in Needham MA.

    Alan has published extensively on the genetic code and protein synthesis, tumour virology, cell biology and cystic fibrosis. He holds a B.A. from Christ’s College, Cambridge and a Ph.D. from the Laboratory of Molecular Biology, Cambridge, England. He is a fellow of the Royal Society of London and of Christ’s College.

  • Christine Soden, Non-Executive Director

    Christine is a non-executive director of Elementis plc, the Cell and Gene Therapy Catapult, Fertility Focus Limited and Futurenova Limited and has previously served as chair of the audit committee at e-therapeutics plc, an AIM listed technology-based drug discovery platform from 2017 to February 2020 and at Provalis plc, a quoted healthcare business from 2000 to 2005. Christine is a Chartered Accountant and holds a degree in Mathematics from the University of Durham.

    Christine Soden is an experienced CFO who brings significant experience in the commercialisation of innovative technology to the Board. She has a strong track record of leading innovative private and public biotechnology, life science and pharmaceutical companies, both private and public.

    From 2015-2020 Christine was CFO and Company Secretary of Acacia Pharma Group plc, a public quoted provider of pharmaceutical products designed to improve the outcomes and recovery for surgical patients. Prior to that role, Christine served as CFO and then non-executive Director of AIM-listed Electrical Geodesics, Inc., which was acquired by Philips NV in 2017. Other CFO and finance leadership roles include Optos plc, BTG plc (former FTSE250 constituent), Oxagen Limited and Celltech Chiroscience Group plc, having started her life-sciences career as Financial Controller of Medeva plc.